Posted by Michael Wonder on 15 Sep 2023
Enhertu recommended for approval in the EU by CHMP for patients with HER2 mutant advanced non-small cell lung cancer
15 September 2023 - Recommendation based on DESTINY-Lung02 trial results which showed AstraZeneca and Daiichi Sankyo’s Enhertu achieved strong and durable tumour responses in previously treated HER2 mutant disease.
AstraZeneca and Daiichi Sankyo’s (trastuzumab deruxtecan) has been recommended for approval in the European Union as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.
